|
Synonyms: BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
nivolumab is an approved drug (FDA (2014), EMA (2015))
Compound class:
Antibody
Comment: Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: nivolumab |
| References |
|
1. Callahan MK, Wolchok JD. (2013)
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol, 94 (1): 41-53. [PMID:23667165] |
|
2. FDA.
FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. Accessed on 18/04/2018. Modified on 18/04/2018. www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm?utm_campaign=Oncology%204%2F16%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=461a88586a9a4db284ceb54da34a6a23&elq=8b10e118e0b249beb2807c129fc264e8&elqaid=3169&elqat=1&elqCampaignId=2374 |
|
3. FDA.
Nivolumab in combination with ipilimumab. Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm |
|
4. Greaves P, Gribben JG. (2013)
The role of B7 family molecules in hematologic malignancy. Blood, 121 (5): 734-44. [PMID:23223433] |
|
5. Hall RD, Gray JE, Chiappori AA. (2013)
Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control, 20 (1): 22-31. [PMID:23302904] |
|
6. Hamid O, Carvajal RD. (2013)
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther, 13 (6): 847-61. [PMID:23421934] |
|
7. Intlekofer AM, Thompson CB. (2013)
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol, 94 (1): 25-39. [PMID:23625198] |
|
8. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012)
T cell coinhibition and immunotherapy in human breast cancer. Discov Med, 14 (77): 229-36. [PMID:23114578] |
|
9. Kline J, Gajewski TF. (2010)
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs, 11 (12): 1354-9. [PMID:21154117] |
|
10. Korman AJ, Srinivasan M, Wang C, Selby MJ, Chen B, Cardarelli JM. (2006)
Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics. Patent number: WO2006121168. Assignee: Ono Pharmaceutical Co. Priority date: 09/05/2005. Publication date: 02/03/2015. |
|
11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 373 (1): 23-34. [PMID:26027431] |
|
12. Luke JJ, Ott PA. (2015)
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget, 6 (6): 3479-92. [PMID:25682878] |
|
13. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al.. (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 373 (19): 1803-13. [PMID:26406148] |
|
14. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378 (14): 1277-1290. [PMID:29562145] |
|
15. O'Sullivan Coyne G, Madan RA, Gulley JL. (2014)
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol, 32 (10): 986-8. [PMID:24590655] |
|
16. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12 (4): 252-64. [PMID:22437870] |
|
17. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med, 372 (21): 2006-17. [PMID:25891304] |
|
18. Tang PA, Heng DY. (2013)
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823] |
|
19. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 27 (4): 450-61. [PMID:25858804] |
